Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Haraldsdottir, SigurdisRafnar, Thorunn
Frankel, Wendy L
Einarsdottir, Sylvia
Sigurdsson, Asgeir
Hampel, Heather
Snaebjornsson, Petur
Masson, Gisli
Weng, Daniel
Arngrimsson, Reynir
Kehr, Birte
Yilmaz, Ahmet
Haraldsson, Stefan
Sulem, Patrick
Stefansson, Tryggvi
Shields, Peter G
Sigurdsson, Fridbjorn
Bekaii-Saab, Tanios
Moller, Pall H
Steinarsdottir, Margret
Alexiusdottir, Kristin
Hitchins, Megan
Pritchard, Colin C
de la Chapelle, Albert
Jonasson, Jon G
Goldberg, Richard M
Stefansson, Kari
Issue Date
2017-05-03
Metadata
Show full item recordCitation
Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. 2017, 8:14755 Nat CommunAbstract
Lynch syndrome, caused by germline mutations in the mismatch repair genes, is associated with increased cancer risk. Here using a large whole-genome sequencing data bank, cancer registry and colorectal tumour bank we determine the prevalence of Lynch syndrome, associated cancer risks and pathogenicity of several variants in the Icelandic population. We use colorectal cancer samples from 1,182 patients diagnosed between 2000-2009. One-hundred and thirty-two (11.2%) tumours are mismatch repair deficient per immunohistochemistry. Twenty-one (1.8%) have Lynch syndrome while 106 (9.0%) have somatic hypermethylation or mutations in the mismatch repair genes. The population prevalence of Lynch syndrome is 0.442%. We discover a translocation disrupting MLH1 and three mutations in MSH6 and PMS2 that increase endometrial, colorectal, brain and ovarian cancer risk. We find thirteen mismatch repair variants of uncertain significance that are not associated with cancer risk. We find that founder mutations in MSH6 and PMS2 prevail in Iceland unlike most other populations.Description
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked FilesAdditional Links
https://www.nature.com/articles/ncomms14755.pdfRights
Archived with thanks to Nature communicationsae974a485f413a2113503eed53cd6c53
10.1038/ncomms14755
Scopus Count
Collections
Related articles
- Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
- Authors: Dillon JL, Gonzalez JL, DeMars L, Bloch KJ, Tafe LJ
- Issue date: 2017 Dec
- Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
- Authors: Lagerstedt-Robinson K, Rohlin A, Aravidis C, Melin B, Nordling M, Stenmark-Askmalm M, Lindblom A, Nilbert M
- Issue date: 2016 Nov
- Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
- Authors: Berginc G, Bracko M, Ravnik-Glavac M, Glavac D
- Issue date: 2009
- Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
- Authors: Najdawi F, Crook A, Maidens J, McEvoy C, Fellowes A, Pickett J, Ho M, Nevell D, McIlroy K, Sheen A, Sioson L, Ahadi M, Turchini J, Clarkson A, Hogg R, Valmadre S, Gard G, Dooley SJ, Scott RJ, Fox SB, Field M, Gill AJ
- Issue date: 2017 Aug
- Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.
- Authors: Ten Broeke SW, van Bavel TC, Jansen AML, Gómez-García E, Hes FJ, van Hest LP, Letteboer TGW, Olderode-Berends MJW, Ruano D, Spruijt L, Suerink M, Tops CM, van Eijk R, Morreau H, van Wezel T, Nielsen M
- Issue date: 2018 Sep